title: Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men.
abstract: 7alpha-Methyl-19-nortestosterone (MENT) is a potent synthetic androgen that is resistant to 5alpha-reductases and therefore less prone to over-stimulate the prostate. It is a good candidate for implant administration in long-term androgen replacement therapy for hypogonadal men or as part of a male contraceptive system. To investigate the pharmacokinetics of MENT after i.m. administration, single i.m. injections of 2, 4 or 8 mg of micronized MENT were given in aqueous suspension to 18 healthy men in two clinics. Blood was sampled frequently for 8 h and 1, 2, 3, 4 and 9 days after the injections. Serum MENT concentrations were determined by radioimmunoassay. Peak MENT concentrations were dose-dependent and were reached about 1-2 h after the injections. Doubling the dose of MENT resulted in an increase of 60% in peak serum MENT concentrations. The mean +/- SE clearance rate was 1790 +/- 140 l/day. The antigonadotrophic activity of MENT was investigated by giving six consecutive daily i.m. injections of 1, 2 or 4 mg of MENT to 24 healthy men in two clinics. Blood was sampled before each injection and up to 24 days after the last injection. Serum testosterone and gonadotrophin concentrations (determined by radioimmunoassay and fluoroimmunoassay respectively) decreased in a dose-dependent and statistically significant manner. The highest dose caused a 74% fall in testosterone, a 70% fall in luteinizing hormone, and a 57% fall in follicle stimulating hormone concentrations. MENT injections did not cause any side-effects. The results show that MENT is a potent antigonadotrophic agent in men.
authors.affiliation: Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Suvisaari
authors.forename: K
authors.initials: K
authors.lastname: Sundaram
authors.forename: G
authors.initials: G
authors.lastname: Noé
authors.forename: N
authors.initials: N
authors.lastname: Kumar
authors.forename: C
authors.initials: C
authors.lastname: Aguillaume
authors.forename: Y Y
authors.initials: YY
authors.lastname: Tsong
authors.forename: P
authors.initials: P
authors.lastname: Lähteenmäki
authors.forename: C W
authors.initials: CW
authors.lastname: Bardin
mesh_terms: D000328:Adult; D002677:Chile; D015331:Cohort Studies; D003282:Contraceptives, Postcoital, Hormonal / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005387:Finland; D005640:Follicle Stimulating Hormone / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007273:Injections, Intramuscular; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D008297:Male; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D013739:Testosterone / Q000097:blood* / Q000378:metabolism; D013997:Time Factors
chemical_list: D003282:Contraceptives, Postcoital, Hormonal; D013739:Testosterone; C064709:trestolone; D009277:Nandrolone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone